Last reviewed · How we verify
NCT07248527: PAN-ICIS
PAN-ICIS Study: ICIS for Early Detection of Infectious Complications in Pancreatic Surgery
trial in Pancreatectomy in 400 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2027
Quick facts
| Lead sponsor | Charles University, Czech Republic |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 November 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 March 2028 |
| Sites | 1 location across Czechia |
Conditions studied
- Pancreatectomy — all drugs for Pancreatectomy →
- Pancreatic Surgery — all drugs for Pancreatic Surgery →
- Intensive Care (ICU) — all drugs for Intensive Care (ICU) →
- Inflamatory Markers — all drugs for Inflamatory Markers →
Sponsor
Charles University, Czech Republic
Who can join
18 and older, any sex, with Pancreatectomy or Pancreatic Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines a new blood test called ICIS, which may help detect infections earlier after pancreatic surgery. Patients will have routine blood samples taken during their hospital stay, with no extra procedures required. By tracking how ICIS changes over time, investigators aim to improve early infection detection, support safer recovery, and reduce postoperative complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07248527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatectomy
Currently open trials in the same condition.
- NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT07157605 — Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) · recruiting
- NCT06714604 — Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC · Phase 3 · recruiting
- NCT05720338 — Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? · Phase 3 · recruiting
Other Charles University, Czech Republic trials
Trials by the same sponsor.
- NCT07475481 — Exercise-Based Strategies for Chronic Back Pain · NA · not yet recruiting
- NCT07468318 — Multimodal Therapy for Somatosensory Tinnitus · NA · not yet recruiting
- NCT07525154 — Development of a Certified Testing Procedure for Hip and Groin Injuries in Athletes · NA · not yet recruiting
- NCT07512570 — Feasibility and Preliminary Effects of a Structured Resistance Training Program in Children Aged 10-14 Years · NA · not yet recruiting
- NCT07424326 — Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07248527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charles University, Czech Republic
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07248527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing